Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.

Enzing, Joost J; Knies, Saskia; Engel, Jop; IJzerman, Maarten J; Sander, Beate; Vreman, Rick; Boer, Bert; Brouwer, Werner B F

Enzing, Joost J; Knies, Saskia; Engel, Jop; IJzerman, Maarten J; Sander, Beate; Vreman, Rick; Boer, Bert; Brouwer, Werner B F.

Afiliação

Enzing JJ; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. enzing@eshpm.eur.nl.
Knies S; Zorginstituut Nederland, Diemen, The Netherlands. enzing@eshpm.eur.nl.
Engel J; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
IJzerman MJ; Zorginstituut Nederland, Diemen, The Netherlands.
Sander B; Zorginstituut Nederland, Diemen, The Netherlands.
Vreman R; Cancer Health Services Research, School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
Boer B; Health Technology and Services Research Department, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
Brouwer WBF; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada.

Cost Eff Resour Alloc ; 20(1): 46, 2022 Aug 31.

Article em En | MEDLINE | ID: mdl-36045377

Palavras-chave

Drug pricing; HTA; HTA agencies; Health Technology Assessment; Pharmaceuticals; Pricing models; Profit margin; Profitability; Reimbursement decision making

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Qualitative_research Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google